[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Vigabatrin.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vigabatrin.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Vigabatrin.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sulthiame.]
[L01BB02, mercaptopurine, Vigabatrin may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Vigabatrin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vigabatrin.]
[L04AX02, thalidomide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Vigabatrin may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Vigabatrin may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vigabatrin.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Vigabatrin.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Vigabatrin.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tilidine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Vigabatrin is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vigabatrin.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Trazodone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Vigabatrin.]
[A03AB12, mepenzolate, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vigabatrin.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Trifluperidol.]
[N05AA05, triflupromazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Vigabatrin.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Vigabatrin.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Vigabatrin.]
[A03BB01, butylscopolamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Vigabatrin.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tubocurarine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ezogabine.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Viloxazine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levetiracetam.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Vigabatrin.]
[G04BD07, tolterodine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Atracurium.]
[S01FA01, atropine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01CA09, azlocillin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Azlocillin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lorcaserin.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Barbital.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Vigabatrin.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Vigabatrin.]
[R06AC06, thonzylamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Diethyl ether.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Benperidol.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vigabatrin.]
[N04AC01, benztropine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Vigabatrin.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Eslicarbazepine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tasimelteon.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Vigabatrin.]
[A03BA03, hyoscyamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Acepromazine.]
[N04AA02, biperiden, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[N06AX11, mirtazapine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Vigabatrin.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Vigabatrin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Vigabatrin.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Bupivacaine.]
[N07BC01, buprenorphine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Vigabatrin.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vigabatrin.]
[R06AX09, azatadine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[R03DA08, bamifylline, Vigabatrin may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The therapeutic efficacy of Vigabatrin can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Beclamide.]
[N06BC01, caffeine, Vigabatrin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Oxybuprocaine.]
[J01XX08, linezolid, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Linezolid.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Safinamide.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Vigabatrin.]
[N04AA11, bornaprine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Brotizolam.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vinylbital.]
[N03AF01, carbamazepine, Carbamazepine may increase the Change in thyroid function activities of Vigabatrin.]
[A03AA03, camylofine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vigabatrin.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Vigabatrin.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Vigabatrin.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, Vigabatrin may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Vigabatrin.]
[R03BB08, revefenacin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Vigabatrin.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cloxazolam.]
[J01DD01, cefotaxime, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vigabatrin.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Yohimbine.]
[J01DB03, cephalothin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Vigabatrin.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Vigabatrin.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Vigabatrin.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lumateperone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Vigabatrin.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dichloralphenazone.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Vigabatrin.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Vigabatrin.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Chlorambucil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vigabatrin.]
[A03AA08, dihexyverine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Dyclonine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Remimazolam.]
[N07XX04, sodium oxybate, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Vigabatrin is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vigabatrin.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Vigabatrin.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Vigabatrin.]
[N06BA10, fenethylline, Vigabatrin may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Trichloroethylene.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vigabatrin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Vigabatrin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Vigabatrin is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Vigabatrin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine.]
[N03AE01, clonazepam, The serum concentration of Clonazepam can be increased when it is combined with Vigabatrin.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Vigabatrin.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Vigabatrin.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Vigabatrin.]
[N05AH02, clozapine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Vigabatrin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Cocaine.]
[C02KB01, metyrosine, Vigabatrin may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Vigabatrin.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Vigabatrin.]
[A03AB10, hexocyclium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ifenprodil.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Vigabatrin.]
[J05AB14, valganciclovir, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Valganciclovir.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vigabatrin.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ketazolam.]
[N03AX09, lamotrigine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Vigabatrin can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Vigabatrin.]
[A03AA04, mebeverine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Medifoxamine.]
[R06AD04, methdilazine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Melperone.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Vigabatrin.]
[S01XA18, cyclosporine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Moclobemide.]
[R06AX02, cyproheptadine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Vigabatrin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Vigabatrin.]
[C01CA23, theodrenaline, Vigabatrin may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vigabatrin.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.]
[G04BD08, solifenacin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Vigabatrin.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxiracetam.]
[N04AA08, dexetimide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Vigabatrin.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Vigabatrin.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Diamorphine.]
[C04AD01, pentifylline, Vigabatrin may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Vigabatrin.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Vigabatrin.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Cinchocaine.]
[A03AA07, dicyclomine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pipamperone.]
[A03AB14, pipenzolate, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Vigabatrin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Vigabatrin.]
[A03AB11, poldine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vigabatrin.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vigabatrin.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pridinol.]
[R06AB03, dimethindene, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Vigabatrin.]
[N06BC02, propentofylline, Vigabatrin may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Proparacaine.]
[R03DA03, proxyphylline, Vigabatrin may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Vigabatrin.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Vigabatrin.]
[C01BA03, disopyramide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Vigabatrin.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Vigabatrin.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Ropivacaine.]
[N06AA16, dothiepin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Vigabatrin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Vigabatrin.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Vigabatrin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Thiopropazate.]
[G04BD01, emepronium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Vigabatrin.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Triclofos.]
[A03AB08, tridihexethyl, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Vigabatrin.]
[N04AA12, tropatepine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Vigabatrin.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Vigabatrin.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Vigabatrin.]
[N05CF02, zolpidem, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Vigabatrin.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vigabatrin.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Vigabatrin.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vigabatrin.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Vigabatrin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Estazolam.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Vigabatrin.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Vigabatrin.]
[N04AA05, profenamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Vigabatrin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Vigabatrin.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Sertindole.]
[R06AX12, terfenadine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluvoxamine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Vigabatrin.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Vigabatrin.]
[G04BD02, flavoxate, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Melitracen.]
[V03AZ01, ethanol, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Vigabatrin.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Vigabatrin.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Vigabatrin.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Vigabatrin is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Gallamine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Vigabatrin.]
[C01CA21, cafedrine, Vigabatrin may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Vigabatrin.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Vigabatrin.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vigabatrin.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Glutethimide.]
[P01BX01, halofantrine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vigabatrin.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Halothane.]
[N05AH04, quetiapine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Allobarbital.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Hexobarbital.]
[R05DA03, hydrocodone, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.]
[N06AA02, imipramine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Vigabatrin.]
[L01CE01, topotecan, Vigabatrin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Milnacipran.]
[A03AA30, piperidolate, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Articaine.]
[V08AB02, iohexol, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Vigabatrin.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Vigabatrin.]
[R06AE01, buclizine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Vigabatrin.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Vigabatrin.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Vigabatrin.]
[J04AC01, isoniazid, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Vigabatrin.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ketanserin.]
[N05AH03, olanzapine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[N04BC09, rotigotine, Vigabatrin may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Nalidixic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Gamolenic acid.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lacosamide.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Vigabatrin.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Lidocaine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Vigabatrin.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Vigabatrin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Vigabatrin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Vigabatrin.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Vigabatrin can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Vigabatrin.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Vigabatrin.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Vigabatrin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Vigabatrin.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Vigabatrin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vigabatrin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Vigabatrin.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vigabatrin.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Vigabatrin.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Metamfetamine.]
[A03AB07, methantheline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Vigabatrin.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Vigabatrin.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Vigabatrin.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Vigabatrin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vigabatrin.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methylene blue.]
[R03DA05, aminophylline, Vigabatrin may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA04, methylphenidate, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Vigabatrin.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Vigabatrin.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Vigabatrin.]
[P01AB01, metronidazole, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Metronidazole.]
[N06AX03, mianserin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Vigabatrin.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Molindone.]
[N06AA09, amitriptyline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Vigabatrin.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Vigabatrin.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Amobarbital.]
[R03BB01, ipratropium bromide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be decreased when it is combined with Vigabatrin.]
[N04BC04, ropinirole, Vigabatrin may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Vigabatrin.]
[N06BA01, amphetamine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Vigabatrin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Vigabatrin.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Iloperidone.]
[J02AA01, amphotericin B, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nialamide.]
[C08CA04, nicardipine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vigabatrin.]
[N04BC05, pramipexole, Vigabatrin may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Vigabatrin.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Vigabatrin.]
[N06AA10, nortriptyline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Opium.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Vigabatrin.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Vigabatrin.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxypertine.]
[A03AB03, oxyphenonium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[M03AC01, pancuronium, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Vigabatrin.]
[N05CC05, paraldehyde, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pargyline.]
[G04BD11, fesoterodine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Vigabatrin.]
[C04AD03, pentoxifylline, Vigabatrin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vigabatrin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Vigabatrin.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Phenoperidine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be decreased when it is combined with Vigabatrin.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Vigabatrin.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pipotiazine.]
[A02BX03, pirenzepine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Piritramide.]
[N02CX01, pizotyline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Vigabatrin.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Prazepam.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Vigabatrin.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.]
[N04AA04, procyclidine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Vigabatrin.]
[N05AA03, promazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Propanidid.]
[A03AB05, propantheline, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Periciazine.]
[N05CM06, propiomazine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Vigabatrin.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vigabatrin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Vigabatrin.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin.]
[N05AX12, aripiprazole, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Vigabatrin.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Mepyramine.]
[C01BA01, quinidine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Vigabatrin.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Vigabatrin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxitriptan.]
[S01FA02, scopolamine, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Vigabatrin.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Vigabatrin.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vigabatrin.]
